Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAMeLot-2 trial of bleximenib + venetoclax + azacitidine in newly diagnosed AML
ISRCTN37340032Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bleximenib in acute myeloid leukemia (AML) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Complete remission rate and Overall survival. Started Apr 2025; status: recruiting.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN37340032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37340032.